Solasia Pharma KK (JP:4597) has released an update.
Solasia Pharma K.K. reports significant year-on-year revenue decline in the first six months of 2024, with a decrease in profit and basic earnings per share. The company maintains a stable equity ratio, while its forward-looking revenue and profit forecasts suggest a potential rebound by the end of the fiscal year. No dividends were paid or forecasted for the fiscal year, reflecting the company’s cautious financial management amid its current performance.
For further insights into JP:4597 stock, check out TipRanks’ Stock Analysis page.
